 |
GC Green Cross (photo = GC Biopharma) |
[Alpha Biz= Reporter Kim Jisun] GC Biopharma announced on the 2nd that it recorded an operating loss of 150 billion won in the first quarter of this year. The deficit increased by 10.5% compared to the same period last year.
First-quarter revenue amounted to 3,568 billion won, up 2.1% from the same period last year. Net loss for the period was 307 billion won.
The increase in operating losses in the first quarter is attributed to the rising costs of personnel and marketing for the direct sales of the immune globulin product "Allyglo (IVIG)," which received approval from the U.S. Food and Drug Administration (FDA) in December last year. The launch of Allyglo in the United States is scheduled for July.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
